Reference:	FOI.3171.20
Subject:	Patient treatment drugs
Date of Request:	15 May 2020

Requested:

Could you please provide me with the following numbers of patients treated in the last 3 months with the following drugs, regardless of disease.

Abatacept [Orencia]
Adalimumab [Amgevita]
Adalimumab [Hulio]
Adalimumab [Humira]
Adalimumab [Hyrimoz]
Adalimumab [Imraldi]
Apremilast [Otezla]
Baricitinib [Olumiant]
Brodalumab [Kyntheum]
Certolizumab [Cimzia]
Dimethyl fumarate [Skilarence]
Etanercept [Benepali]
Etanercept [Enbrel]
Etanercept [Erelzi]
Golimumab [Simponi]
Guselkumab [Tremfya]
Infliximab [Flixabi]
Infliximab [Inflectra]
Infliximab [Remicade]
Infliximab [Remsima]
Ixekizumab [Taltz]
Risankizumab [Skyrizi]
Rituximab [MabThera]
Rituximab [Rixathon]
Rituximab [Truxima]
Sarilumab [Kevzara]
Secukinumab [Cosentyx]
Tildrakizumab [Ilumetri]
Tocilizumab [Ro Actemra]
Tofacitinib [Xeljanz]
Upadacitinib [Rinvoq]
Ustekinumab [Stelara]

Response:

Hywel Dda University Health Board (UHB) provides, within the table below, the drug treatment and number of patients for the period 1 February 2020 to 30 April 2020 as requested.

Drug	Number of patients
Abatacept [Orencia]	68
Adalimumab [Amgevita]	97
Adalimumab [Hulio]	0
Adalimumab [Humira]	58
Adalimumab [Hyrimoz]	0
Adalimumab [Imraldi]	94
Apremilast [Otezla]	*
Baricitinib [Olumiant]	60
Brodalumab [Kyntheum]	0
Certolizumab [Cimzia]	35
Dimethyl fumarate [Skilarence]	*
Etanercept [Benepali]	179
Etanercept [Enbrel]	27
Etanercept [Erelzi]	19
Golimumab [Simponi]	21
Guselkumab [Tremfya]	0
Infliximab [Flixabi]	0
Infliximab [Inflectra]	149
Infliximab [Remicade]	*
Infliximab [Remsima]	0
Ixekizumab [Taltz]	0
Risankizumab [Skyrizi]	0
Rituximab [MabThera]	22
Rituximab [Rixathon]	0
Rituximab [Truxima]	37
Sarilumab [Kevzara]	0
Secukinumab [Cosentyx]	41
Tildrakizumab [Ilumetri]	0
Tocilizumab [Ro Actemra]	81
Tofacitinib [Xeljanz]	*
Upadacitinib [Rinvoq]	0
Ustekinumab [Stelara]	57

Where the figures in the table have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the Data Protection Act 2018/ General Data Protection Regulations 2016 (GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/General Data Protection Regulations 2016 defines personal data as data which relates to a living individual who can be identified solely from that data or from that data and other information which is in the possession of the data controller.